Metraipolis › archive › dc_554fbb4abc84

Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients With Type 2 Diabetes in a Real-World Setting — Europe PMC PMID:41602226

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41602226
DOI: 10.7759/cureus.100108
License (as archived): solo-consultazione
Archived: 2026-11-07T09:23:44.830Z
SHA-256 of the archived text: 7a804a738c6d367ccb4a78fe4829644bdf67296c526f7d0d1e5d8868208d1318
Stable URL of this page: https://metraipolis.com/documento/dc_554fbb4abc84

How to cite

Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients With Type 2 Diabetes in a Real-World Setting — Europe PMC PMID:41602226 — Europe PMC (en), https://europepmc.org/article/MED/41602226 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_554fbb4abc84 (Metraipolis archive dc_554fbb4abc84, sha256 7a804a738c6d367ccb4a78fe4829644bdf67296c526f7d0d1e5d8868208d1318)

BibTeX

@misc{dc554fbb4abc84,
  title = {Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients With Type 2 Diabetes in a Real-World Setting — Europe PMC PMID:41602226},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41602226},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_554fbb4abc84; sha256 7a804a738c6d367ccb4a78fe4829644bdf67296c526f7d0d1e5d8868208d1318},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41602226. Agents can read the archived copy with the MCP tool read_document.